Payment overview · 2025
General Payments
$65,342.55
143 reported records · 20 companies
Healthcare provider profile · identity verified
Raymonda Rastegar, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Cardiovascular Disease · NEW YORK, NY · NPI 1609888403
Verified facts
What the public records show
CMS Open Payments records show Raymonda Rastegar, M.D. received $65,342.55 in general payments during 2025 across 143 reported records.
Novo Nordisk Inc accounted for 95.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 26 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Nexletol, Ozempic, Wegovy.
Actelion Pharmaceuticals US, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OPSUMIT as an associated drug or biological on 18955 records involving 8899 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Opsumit by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 111 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 262 claims for Eliquis by this doctor in 2024.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLETOL as an associated drug or biological on 24230 records involving 12642 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Nexletol by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 111 claims for Jardiance by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 224 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Rybelsus by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Wegovy as an associated drug or biological on 183056 records involving 75256 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Wegovy by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 262 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $62,646.66 | 95.9% | 33 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $365.98 | 0.6% | 13 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $320.61 | 0.5% | 14 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $227.60 | 0.3% | 9 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $226.16 | 0.3% | 9 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $206.08 | 0.3% | 10 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $192.87 | 0.3% | 8 | 2025 |
| BIOTRONIK INC. | Unresolved — no canonical attribution shown | $160.81 | 0.2% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $156.23 | 0.2% | 5 | 2025 |
| BridgeBio Pharma, Inc. | Unresolved — no canonical attribution shown | $153.52 | 0.2% | 7 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $140.88 | 0.2% | 12 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $110.75 | 0.2% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $110.65 | 0.2% | 4 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $79.81 | 0.1% | 3 | 2025 |
| MEDICOMP INC | Unresolved — no canonical attribution shown | $56.82 | 0.1% | 2 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $50.53 | 0.1% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $42.32 | 0.1% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $39.48 | 0.1% | 2 | 2025 |
| Currax Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $32.16 | 0.1% | 2 | 2025 |
| HEARTFLOW, INC. | Unresolved — no canonical attribution shown | $22.63 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $53,782.31 | 10 |
| Travel and Lodging | $7,619.02 | 12 |
| Food and Beverage | $3,941.22 | 121 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $47,747.77 | 22 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $320.61 | 14 | 2025 |
Source payment records
|
|||||
| WAINUA Normalized: wainua |
Drug | AstraZeneca Pharmaceuticals LP | $241.48 | 6 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $227.60 | 9 | 2025 |
Source payment records
|
|||||
| AMVUTTRA Normalized: amvuttra |
Drug | Alnylam Pharmaceuticals Inc. | $226.16 | 9 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $206.08 | 10 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $172.86 | 7 | 2025 |
Source payment records
|
|||||
| BIOMONITOR Normalized: biomonitor |
Device | BIOTRONIK INC. | $160.81 | 1 | 2025 |
Source payment records
|
|||||
| LOKELMA Normalized: lokelma |
Drug | AstraZeneca Pharmaceuticals LP | $156.40 | 7 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $156.23 | 5 | 2025 |
Source payment records
|
|||||
| Attruby Normalized: attruby |
Drug | BridgeBio Pharma, Inc. | $153.52 | 7 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $130.71 | 8 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $110.75 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $110.65 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $99.97 | 5 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $79.81 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $59.70 | 2 | 2025 |
Source payment records
|
|||||
| TELEPATCH CARDIAC MONITOR Normalized: telepatch cardiac monitor |
Device | MEDICOMP INC | $56.82 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $54.54 | 2 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $52.49 | 6 | 2025 |
Source payment records
|
|||||
| OPSYNVI Normalized: opsynvi |
Drug | Actelion Pharmaceuticals US, Inc. | $50.53 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $42.32 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $39.48 | 2 | 2025 |
Source payment records
|
|||||
| CONTRAVE Normalized: contrave |
Drug | Currax Pharmaceuticals LLC | $32.16 | 2 | 2025 |
Source payment records
|
|||||
| FFRct Normalized: ffrct |
Device | HEARTFLOW, INC. | $22.63 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $18.75 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 262 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 39 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 111 | exact normalized | Medicare Part D |
| NEXLETOL nexletol |
2025 | Nexletol | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 224 | exact normalized | Medicare Part D |
| Wegovy wegovy |
2025 | Wegovy | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Actelion Pharmaceuticals US, Inc. Exact reporting entity; no affiliate inference |
2025 | OPSUMIT open payments reported associated product |
CMS Open Payments — General Payments 18955 supporting records · 8899 recipient NPIs · example record 1174163978 |
Opsumit · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
39 | 14 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
111 | 26 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
262 | 70 |
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLETOL open payments reported associated product |
CMS Open Payments — General Payments 24230 supporting records · 12642 recipient NPIs · example record 1243949989 |
Nexletol · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
111 | 26 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
71 | 22 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
224 | 42 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Wegovy open payments reported associated product |
CMS Open Payments — General Payments 183056 supporting records · 75256 recipient NPIs · example record 1188130070 |
Wegovy · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
262 | 70 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
21 | 18 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 917 | 266 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 764 | 224 |
| Amlodipine Besylate | Amlodipine Besylate | 572 | 174 |
| Metoprolol Succinate | Metoprolol Succinate | 494 | 152 |
| Ezetimibe | Ezetimibe | 271 | 83 |
| Eliquis | Apixaban | 262 | 70 |
| Ozempic | Semaglutide | 224 | 42 |
| Clopidogrel | Clopidogrel Bisulfate | 220 | 61 |
| Losartan Potassium | Losartan Potassium | 202 | 61 |
| Atenolol | Atenolol | 156 | 46 |
| Furosemide | Furosemide | 144 | 54 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 136 | 43 |
| Nebivolol Hcl | Nebivolol Hcl | 127 | 36 |
| Repatha Sureclick | Evolocumab | 126 | 23 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 122 | 32 |
| Carvedilol | Carvedilol | 115 | 32 |
| Jardiance | Empagliflozin | 111 | 26 |
| Metformin Hcl | Metformin Hcl | 106 | 37 |
| Hydrochlorothiazide | Hydrochlorothiazide | 91 | 33 |
| Praluent Pen | Alirocumab | 91 | 14 |
| Valsartan | Valsartan | 90 | 25 |
| Lisinopril | Lisinopril | 87 | 22 |
| Levothyroxine Sodium | Levothyroxine Sodium | 84 | 28 |
| Ramipril | Ramipril | 84 | 25 |
| Escitalopram Oxalate | Escitalopram Oxalate | 76 | 27 |
| Entresto | Sacubitril/Valsartan | 71 | 22 |
| Omeprazole | Omeprazole | 69 | 28 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 63 | 16 |
| Synthroid | Levothyroxine Sodium | 63 | 18 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 62 | 16 |
| Simvastatin | Simvastatin | 58 | 21 |
| Pravastatin Sodium | Pravastatin Sodium | 56 | 21 |
| Pantoprazole Sodium | Pantoprazole Sodium | 55 | 19 |
| Xarelto | Rivaroxaban | 55 | 18 |
| Zolpidem Tartrate | Zolpidem Tartrate | 54 | 13 |
| Amiodarone Hcl | Amiodarone Hcl | 52 | 24 |
| Azithromycin | Azithromycin | 51 | 36 |
| Ranolazine Er | Ranolazine | 49 | 19 |
| Spironolactone | Spironolactone | 49 | 17 |
| Nifedipine Er | Nifedipine | 47 | 12 |
| Verapamil Er | Verapamil Hcl | 43 | 11 |
| Livalo | Pitavastatin Calcium | 41 | suppressed |
| Vascepa | Icosapent Ethyl | 41 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 40 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 39 | 14 |
| Finasteride | Finasteride | 35 | suppressed |
| Nexletol | Bempedoic Acid | 35 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 34 | 13 |
| Amoxicillin | Amoxicillin | 33 | 17 |
| Minoxidil | Minoxidil | 33 | 12 |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 32 | suppressed |
| Famotidine | Famotidine | 32 | 13 |
| Telmisartan | Telmisartan | 32 | suppressed |
| Rybelsus | Semaglutide | 31 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 31 | suppressed |
| Alprazolam | Alprazolam | 30 | 13 |
| Irbesartan | Irbesartan | 30 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 30 | suppressed |
| Allopurinol | Allopurinol | 29 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 29 | suppressed |
| Gabapentin | Gabapentin | 29 | 16 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 27 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 27 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 27 | suppressed |
| Lorazepam | Lorazepam | 26 | 11 |
| Midodrine Hcl | Midodrine Hcl | 26 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 25 | 11 |
| Edarbi | Azilsartan Medoxomil | 24 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 24 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 23 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 23 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 22 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 22 | suppressed |
| Wegovy | Semaglutide | 22 | suppressed |
| Multaq | Dronedarone Hcl | 21 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 21 | 18 |
| Bystolic | Nebivolol Hcl | 20 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 20 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 20 | suppressed |
| Prednisone | Prednisone | 20 | 16 |
| Bupropion Xl | Bupropion Hcl | 18 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 18 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 18 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 17 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 17 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 16 | suppressed |
| Myrbetriq | Mirabegron | 16 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 16 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 16 | suppressed |
| Chlorthalidone | Chlorthalidone | 15 | suppressed |
| Clonazepam | Clonazepam | 14 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 13 | suppressed |
| Carvedilol Er | Carvedilol Phosphate | 12 | suppressed |
| Opsumit | Macitentan | 12 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 12 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 11 | suppressed |
| Inpefa | Sotagliflozin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $65,342.55 · 143 records | Novo Nordisk Inc | AMVUTTRA, Attruby, BIOMONITOR, CAMZYOS, CAPVAXIVE, CONTRAVE, ELIQUIS, FARXIGA, FFRct, JARDIANCE, Kerendia, Korlym, LEQVIO, LOKELMA, MOUNJARO, NEXLETOL, NURTEC ODT, OPSYNVI, Ozempic, REPATHA, TELEPATCH CARDIAC MONITOR, TRELEGY ELLIPTA, VERQUVO, WAINUA, Wegovy, ZEPBOUND | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Actelion Pharmaceuticals US, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error